Indegene Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Published 25 Aug 2026 | Healthcare Services | Market Cap: ₹13.7K Cr
Indegene Limited expects organic growth in FY27 to be better than FY26, with an acceleration in the second half of FY27. Indegene expects better organic growth in FY27 compared to FY26, with acceleration in the second half of the year.
From Indegene's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Price
₹562
Market Cap
₹13.7K Cr
P/E Ratio
32.9
Revenue Rank
Margin Rank
How does Indegene rank in Healthcare Services?
Compare Indegene against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Indegene — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.0K Cr, net profit ₹80 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 3- →Indegene Limited expects organic growth in FY27 to be better than FY26, with an acceleration in the second half of FY27.
- →Best first quarter sequential growth in 4 years with a broadening client base and strong pipeline.
- →The outcome-based omnichannel engagement deal starting to contribute revenues from Q3 FY27, boosting growth and profitability.
- →Expansion efforts focus on deepening relationships with existing clients and converting pipeline into signed deals.
- →Continued investment in Gen AI platforms embedded across operations to drive efficiency, cost reduction, and enhanced customer outcomes.
- →Growth driven by broadening customer base, with active customers rising to 105 and increased revenues from accounts beyond the top 20.
- →Large strategic deals (like the $10 million+ omnichannel contract and portfolio management for a $1 billion pharma brand portfolio) poised to boost future revenues.
- →Industry growth supported by AI as a structural tailwind to Indegene’s model, advancing scalability and performance.
📈 Profitability & Margins
Rank 1- →Indegene expects better organic growth in FY27 compared to FY26, with acceleration in the second half of the year.
- →The outcome-based omnichannel engagement deal starting revenue recognition in Q3 FY27 is anticipated to boost both growth and profitability.
- →EBITDA margin is forecasted to normalize to historical levels of 19%-20% by Q4 FY27, supported by revenue ramp-up and productivity benefits from workforce transformation and Gen AI initiatives.
- →Investments in go-to-market, technology, and strategic deals cause near-term margin compression but are expected to reverse within 6 quarters from October 2025 (i.e., by Q4 FY27).
- →Profit after tax (PAT) showed strong sequential growth (+45.9% sequentially), indicating profitability momentum.
- →EPS growth is expected to improve in line with revenue growth and margin recovery, driven by signed deals and operational efficiencies.
🏗️ Capital Expenditure Plans
Yes- →Indegene continues to invest heavily in its proprietary tech stack, including building a robust data layer integrating various data sources (Indegene data universe).
- →Investments in Cortex platform for knowledge engineering, separating SME layer from technical layer to iteratively use the right AI models per use case.
- →Ongoing development of agent layers (e.g., Content Super App, Medical Writing platform) to automate and scale pharma commercial and medical activities.
- →Workforce transformation investments aimed at long-term employee cost optimization and managing wage hikes.
- →Strategic deals such as Tectonic and large omnichannel engagements require upfront costs with revenue recognition expected in Q3 FY27 and onwards.
- →Indegene currently expenses technology and platform investments rather than capitalizing them to keep P&L and balance sheet clean, though capitalization could be considered.
- →Overall, investments are strategic and focused on enabling AI-led platform growth, driving outcomes, and deepening customer relationships with long-term value.
💰 Fundraising & Capital Structure
No information📋 Order Book & Pipeline
Yes- →Most engagements at Indegene are hybrid contracts with an early FTE component and revenue ramp-up over 3 to 4 quarters.
- →A large omnichannel engagement deal (over $10 million ACV) is pure outcome-based with revenue recognition deferred by about 3 quarters, expected to start from Q3.
- →Costs for this large outcome-based deal have been incurred since last quarter, implying future revenue will improve margins.
- →Indegene is seeing encouraging revenue upticks shared by clients over the past 5 months.
- →Large strategic deals, including managing a $1 billion+ pharma brand portfolio in the US, have been won with revenue expected to flow strongly in the second half.
- →The company anticipates order book and revenue visibility to improve in the second half of the fiscal year with these deals.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Indegene Q1 FY27 results?
Indegene Limited expects organic growth in FY27 to be better than FY26, with an acceleration in the second half of FY27. Indegene expects better organic growth in FY27 compared to FY26, with acceleration in the second half of the year.
What is Indegene share price analysis?
Indegene currently shows a below-average growth signal. The stock trades at a P/E of 32.9 with a market cap of ₹13,679 Cr. Investors should review the full earnings analysis for detailed insights.
Is Indegene planning capital expenditure?
Indegene continues to invest heavily in its proprietary tech stack, including building a robust data layer integrating various data sources (Indegene data universe).
Keep Indegene on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.